Curcumin nanodisks: formulation and characterization.
Nanodisks (NDs) are nanoscale, disk-shaped phospholipid bilayers whose edge is stabilized by apolipoproteins. In the present study, NDs were formulated with the bioactive polyphenol curcumin at a 6:1 phospholipid-to-curcumin molar ratio. Atomic force microscopy revealed that curcumin-NDs are particles with diameters <50 nm and the thickness of a phospholipid bilayer. When formulated in NDs, curcumin is water soluble and gives rise to a characteristic absorbance spectrum with a peak centered at 420 nm. Fluorescence spectroscopy of curcumin-NDs provided evidence of self-quenching. Incubation of curcumin-NDs with empty NDs relieved the self-quenching, indicating redistribution of curcumin between curcumin-loaded and empty NDs. In HepG2 cells, curcumin-NDs mediated enhanced cell growth inhibition as compared with free curcumin. In a cell culture model of mantle cell lymphoma, curcumin-NDs were a more potent inducer of apoptosis than free curcumin. The nanoscale size of the complexes, combined with their ability to solubilize curcumin, indicates NDs may have in vivo therapeutic applications.


BACKGROUND
Nanodisks (NDs), disk-shaped phospholipid bilayers stabilized by apolipoproteins, are shown entrap curcumin and improve its delivery to HepG2 and mantle cell lymphoma cells in culture. These novel nanocomplexes demonstrate interesting therapeutic application potentials.
Ghosh
Mistuni
M
Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, California, USA.
Singh
Amareshwar T K
AT
Xu
Wenwei
W
Sulchek
Todd
T
Gordon
Leo I
LI
Ryan
Robert O
RO
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D000975:Antioxidants / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D003474:Curcumin / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D004337:Drug Carriers / Q000737:chemistry* / Q000494:pharmacology; D056945:Hep G2 Cells; D006801:Humans; D049329:Nanostructures / Q000737:chemistry*
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D000975:Antioxidants; D004337:Drug Carriers; D003474:Curcumin
Expert Opin Drug Deliv. 2008 Mar;5(3):343-51
18318655
J Nanobiotechnology. 2007 Apr 17;5:3
17439648
Antimicrob Agents Chemother. 2006 Apr;50(4):1238-44
16569834
Cell Mol Life Sci. 2008 Jun;65(11):1631-52
18324353
Int J Cancer. 2009 Jul 1;125(1):1-8
19326431
Antioxid Redox Signal. 2008 Mar;10(3):511-45
18370854
Altern Med Rev. 2009 Jun;14(2):141-53
19594223
Int J Oncol. 2008 May;32(5):1119-23
18425340
Photochem Photobiol. 2000 Nov;72(5):625-31
11107847
Med Res Rev. 2010 Sep;30(5):818-60
20027668
Cancer Lett. 2008 Oct 8;269(2):199-225
18479807
Int J Pharm. 2007 Jul 18;339(1-2):246-50
17412536
Biochem Biophys Res Commun. 2009 Feb 6;379(2):466-9
19114030
J Lipid Res. 2006 Feb;47(2):260-7
16314670
Clin Cancer Res. 2008 Jul 15;14(14):4491-9
18628464
Mol Pharm. 2007 Nov-Dec;4(6):807-18
17999464
Photochem Photobiol. 1994 Mar;59(3):295-302
8016208
Cancer Chemother Pharmacol. 2007 Jul;60(2):171-7
17051370
Eur J Biochem. 2001 Jul;268(13):3728-35
11432739
Protein Expr Purif. 2003 Jan;27(1):98-103
12509990
Br J Haematol. 2010 Jul;150(2):158-69
20507312
Br J Nutr. 2010 Jun;103(11):1545-57
20100380
Curr Drug Discov Technol. 2009 Sep;6(3):192-9
19496751
Anticancer Res. 2010 Apr;30(4):1131-6
20530418